News

For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.

8th Mar 13

Pharmaxis Announces Milestone in Phase 3 Trial for Bronchiectasis

Specialty pharmaceutical company Pharmaxis (ASX: PXS) today announced formal completion of a 52 week, Phase 3 international trial assessing the effectiveness of Bronchitol®in people with bronchiectasis. The last participant has completed the final clinical visit in the trial which began in October 2009.

 

Read full media release - pdf
31st Jan 13

Pharmaxis Announces US$40 million Financing Agreement with NovaQuest

Pharmaceutical company Pharmaxis Ltd (ASX: PXS) is pleased to announce the signing of a Financing Agreement with NovaQuest Pharma Opportunities Fund III, LP (NovaQuest) under which NovaQuest will invest up to US$40 million to support the continued development, manufacturing and commercialisation of Bronchitol for cystic fibrosis in the EU and US. 

 

Read full media release - pdf
31st Jan 13

Pharmaxis Receives Negative Recommendation from PADAC

Pharmaceutical company Pharmaxis (ASX: PXS) today announced it has received a negative recommendation from a Committee advising the US Food and Drug Administration (FDA) on the use of Bronchitol® for cystic fibrosis patients in the United States.

 

Read full media release - pdf